<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-15T15:31:35Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/dwn5829g43.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/dwn5829g43.1</identifier>
                <datestamp>2025-05-06T05:14:24Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Dart, John</dc:creator>
    <dc:title>Acanthamoeba keratitis treatment: an 8 case summary</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>This is a spreadsheet workbook includes the data from all recorded treatment changes for a sample of 8 patients having had an episode of Acanthamoeba keratitis managed using  individualised treatment delivery, as opposed to per-protocol delivery, for a sample (one in every sixth patient of a 48 patient consecutive series) from London (Moorfields Eye Hospital) treated patients between 1997 and 2011. This series is from a dataset used in a previous study (Papa V, Rama P, Radford C, Minassian DC, Dart JKG. Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases. Br J Ophthalmol. Apr 2020;104(4):575-581. doi:10.1136/bjophthalmol-2019-314485). The first worksheet &quot;Comparison of protocols and cases&quot; compares the treatment delivery for these cases to that of the protocol specifications for critical keratitis treatment points. The protocol specifications are from the treatment delivery protocol used in a published Phase 3 Trial (Dart JKG, Papa V, Rama P, et al. The Orphan Drug for Acanthamoeba Keratitis (ODAK) Trial: PHMB 0.08% (Polihexanide) and Placebo versus PHMB 0.02% and Propamidine 0.1. Ophthalmology. Mar 2024;131(3):277-287. doi:10.1016/j.ophtha.2023.09.031). The second worksheet includes all the treatment changes throughout the course of treatment to the last follow-up visit for each of the 8 cases. </dc:description>
    <dc:subject>Acanthamoeba Keratitis</dc:subject>
    <dc:subject>Management of Acanthamoeba Keratitis</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/dwn5829g43.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/dwn5829g43.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/dwn5829g43</dc:relation>
    <dc:date>2025-05-06T05:14:24Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
